Citigroup’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Citigroup’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,982	Closed	-$2K	–	6848
2022 Q1	$2K	Buy	+2,982	New	+$1.56K	﹤0.01%	6123
2021 Q3	–	Sell	-84	Closed	–	–	6457
2021 Q2	$0	Sell	84 -456	-84%	-$1.89K	﹤0.01%	6522
2021 Q1	$3K	Sell	540 -623	-54%	-$5.52K	﹤0.01%	6027
2020 Q4	$9K	Buy	+1,163	New	+$10.7K	﹤0.01%	6993

Other funds holding MTCR

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citigroup's MTCR Position: Q2 2022 in Review

Citigroup sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2022, closing a stake of 2,982 shares — an estimated $2K sold.

Citigroup first reported a position in MTCR in Q4 2020 and held it in 4 quarters. The position peaked at $9K in Q4 2020. 25 funds tracked by Wall St. Rank hold MTCR as of Q2 2022.

Citigroup reported no remaining Metacrine, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Citigroup sold 2,982 Metacrine, Inc. Common Stock shares in Q2 2022, an estimated $2K.
Citigroup first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Citigroup's Metacrine, Inc. Common Stock position peaked at $9K in Q4 2020.
25 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.